Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T cell–mediated antibody-dependent cellular cytotoxicity provides a therapeutic approach for solid cancers
Alon Richter, Shahar Dotan, Petr Shendrik, Diana Rasoulouniriana, Amichai Zarfin, Nadine Santana-Magal, Aseel Khateeb, Adi Frisch, Gal Verbin, Ariel Galor, Eran Sadot, Oran Zlotnik, Avishai Maliah, Ori Moskowitz, Tom Ben-Dov, Maya Halpern, Chen Luxenburg, Alexander Leithner, Yu Zhang, Natalia T. Freund, Merav Cohen, Carmit Levy, Matthew H. Spitzer, Raya Sorkin, Michael L. Dustin, Peleg Rider, Yaron Carmi
Alon Richter, Shahar Dotan, Petr Shendrik, Diana Rasoulouniriana, Amichai Zarfin, Nadine Santana-Magal, Aseel Khateeb, Adi Frisch, Gal Verbin, Ariel Galor, Eran Sadot, Oran Zlotnik, Avishai Maliah, Ori Moskowitz, Tom Ben-Dov, Maya Halpern, Chen Luxenburg, Alexander Leithner, Yu Zhang, Natalia T. Freund, Merav Cohen, Carmit Levy, Matthew H. Spitzer, Raya Sorkin, Michael L. Dustin, Peleg Rider, Yaron Carmi
View: Text | PDF
Research Article Immunology Oncology

T cell–mediated antibody-dependent cellular cytotoxicity provides a therapeutic approach for solid cancers

  • Text
  • PDF
Abstract

The clinical success of chimeric antigen receptor T cells in treating hematological malignancies has highlighted the immense therapeutic potential of engineering T cells with synthetic receptors. However, the limited availability of tumor-specific antigens and the poor ability of T cells to infiltrate solid tumor cores remain major obstacles for applying this approach to solid tumors. In this study, we identify a subset of CD8+ T cells at inflammatory sites that acquire FcγRI through trogocytosis from infiltrating monocytes, enabling them to perform transient TCR-independent antibody-dependent cellular cytotoxicity (ADCC). Analysis of FcγRI signaling in these T cells revealed that phosphorylation occurs only when antigen density on the membrane exceeds 30 molecules/μm². Exploiting this threshold, we engineered peripheral blood CD8+ T cells to express a modified FcγRI receptor, allowing them to selectively kill tumor cells while largely sparing healthy tissues expressing normal physiological levels of the same antigen. Moreover, expression of FcγRI receptor in T cells was associated with reduced basement membrane interactions, enhancing their capacity to infiltrate tumors and establish long-term immune memory. Collectively, this work establishes T cell–mediated ADCC as a potent therapeutic strategy that leverages antigen density, rather than antigen identity, to achieve selective cancer targeting.

Authors

Alon Richter, Shahar Dotan, Petr Shendrik, Diana Rasoulouniriana, Amichai Zarfin, Nadine Santana-Magal, Aseel Khateeb, Adi Frisch, Gal Verbin, Ariel Galor, Eran Sadot, Oran Zlotnik, Avishai Maliah, Ori Moskowitz, Tom Ben-Dov, Maya Halpern, Chen Luxenburg, Alexander Leithner, Yu Zhang, Natalia T. Freund, Merav Cohen, Carmit Levy, Matthew H. Spitzer, Raya Sorkin, Michael L. Dustin, Peleg Rider, Yaron Carmi

×

Figure 6

T cell ADCC selectively targets cells exceeding a defined antigen-density threshold.

Options: View larger image (or click on image) Download as PowerPoint
T cell ADCC selectively targets cells exceeding a defined antigen-densit...
(A) FACS absolute quantification of antigen expression on HT29 tumor cells (n = 6). (B) Normalized HT29 cell confluence following incubation with transduced human T cells in combination with cetuximab or trastuzumab or sofituzumab (n = 4 for each combination). (C) Mean synapse length between AG2G-transduced T cells and tumor cells in the presence of relevant antibody (cetuximab), irrelevant antibody (trastuzumab), and no antibody (n = 18). (D) Representative SIM of HT29 tumor cells incubated overnight with AG2G-transduced T cells. Original magnification, ×630. (E) Integrated density of HER2 on SLBs during interaction with transduced T cells (3 donors, n = 8 cells each). (F) Normalized epithelial cell count following incubation with AG2G-, CAR HER2–, or sham-transduced T cells in combination with trastuzumab (n = 4). (G) Tumor size following treatment with AG2G and relevant antibody (anti–mouse HER2), irrelevant antibody (rituximab), or sham and relevant antibody (n = 4). Experiments were repeated at least 3 independent times. *P < 0.05; ***P < 0.0001; ****P < 0.00001 by ANOVA with Tukey’s correction for multiple comparisons. Error bars represent SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts